The prospective data collection initiative on on small bowel, colorectal and anal cancer - a prospective observational cohort study.

The prospective data collection initiative on on small bowel, colorectal and anal cancer - a prospective observational cohort study. - PLCRC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54603

Enrollment

100000

Registered

2014-02-06

Start date

2014-07-08

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anal cancer Colorectal Cancer small bowel cancer intestinal cancer

Interventions

nvt

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age of 18 years or older Histological proof of colorectal, small bowel or anal cancer, or a strong suspicion after imaging Informed consent for longitudinal observational data collection

Exclusion criteria

Exclusion criteria: Mentally incompetent

Design outcomes

Primary

Measure	Time frame
1. Clinical parameters: medical history, co-morbidity, medication use, basic physical examination, laboratory results, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and adverse events. 2. Clinical endpoints: treatment effect, adenoma-free survival, disease-free survival, progression-free survival, overall survival and grade 3/4 (serious) adverse events. 3. Patient reported outcomes: health related quality of life, work participation and work ability. 4. Biobanking of blood and tumor tissue	—

Measure

Time frame

1. Clinical parameters: medical history, co-morbidity, medication use, basic physical examination, laboratory results, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and adverse events. 2. Clinical endpoints: treatment effect, adenoma-free survival, disease-free survival, progression-free survival, overall survival and grade 3/4 (serious) adverse events. 3. Patient reported outcomes: health related quality of life, work participation and work ability. 4. Biobanking of blood and tumor tissue

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Contacts

Public ContactA.J.S. van Tetering

Universitair Medisch Centrum Utrecht

a.j.s.houben@umcutrecht.nl0646919566

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 15, 2026